Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of ...
About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate ...
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will ...
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95% ...
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose ...
—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...
The US Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) now recommends a pneumococcal conjugate vaccine (PCV) for all PCV-naive adults aged 50 ...
1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...
Pneumococcal infections can be very serious – they include pneumonia, meningitis, and bacteremia (a blood infection), as well as usually less worrying ear infections and sinus infections. To protect ...
The National Health Security Office (NHSO) has clarified its decision to pilot the pneumococcal conjugate vaccine (PCV) ...
Paediatricians have urged the National Health Security Office (NHSO) to explain why the pneumococcal conjugate vaccine (PCV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results